Drugs Made In America Acquisition II Corp. (DMII) Financial Statements
Industry: Blank Checks
In fiscal 2025, Drugs Made In America Acquisition II reported revenue of $0. Net income was $4.2M, or $0.15 per diluted share. Operating activities generated -$1.0M of cash. At fiscal year end, Drugs Made In America Acquisition II held $505.0M in total assets against $17.8M in total liabilities, including $223 of cash and equivalents.
Open the full interactive Drugs Made In America Acquisition II financials → Quarterly statements, key ratios, valuation history and price charts.
Drugs Made In America Acquisition II Key Stats
| Share Price | $10.19 |
|---|---|
| Market Cap | $509.5M |
| P/E Ratio | 67.9 |
| 52-Week Range | $9.87 – $10.19 |
| Shares Outstanding | 50.0 million (basic, 2026 Q2) |
Drugs Made In America Acquisition II Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$488,385 |
| Pre-Tax Income | $4.2M |
| Net Income | $4.2M |
| Diluted EPS | $0.15 |
Drugs Made In America Acquisition II Quarterly Results
| 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income | -$46,158 | $4.3M | $4.4M |
| Diluted EPS | -$0.00 | $0.07 | $0.07 |
Drugs Made In America Acquisition II Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $223 |
| Current Assets | $26,037 |
| Total Assets | $505.0M |
| Current Liabilities | $300,864 |
| Total Liabilities | $17.8M |
| Shareholders' Equity | -$17.8M |
Drugs Made In America Acquisition II Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$1.0M |
| Cash From Investing | -$500.0M |
| Cash From Financing | $501.0M |
Figures from Drugs Made In America Acquisition II's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Drugs Made In America Acquisition II financials page for every line item.
Drugs Made In America Acquisition II Company Profile
| Ticker | DMII |
|---|---|
| Exchange | Nasdaq |
| Industry | Blank Checks |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0002040475 |
Frequently Asked Questions
What was Drugs Made In America Acquisition II's revenue in fiscal 2025?
Drugs Made In America Acquisition II (DMII) reported revenue of $0 for fiscal 2025.
What was Drugs Made In America Acquisition II's net income in fiscal 2025?
Drugs Made In America Acquisition II reported net income of $4.2M for fiscal 2025.
What was Drugs Made In America Acquisition II's earnings per share (EPS) in fiscal 2025?
Drugs Made In America Acquisition II's diluted EPS was $0.15 for fiscal 2025 (adjusted for any later stock splits).
What was Drugs Made In America Acquisition II's revenue last quarter?
In its most recent reported quarter (2026 Q2), Drugs Made In America Acquisition II reported revenue of $0.
How many shares of Drugs Made In America Acquisition II are outstanding?
Drugs Made In America Acquisition II reported a weighted average of 50.0 million basic shares outstanding in 2026 Q2.
What is Drugs Made In America Acquisition II's market cap?
Based on its latest closing price, Drugs Made In America Acquisition II (DMII) has a market capitalization of about $509.5M.
When does Drugs Made In America Acquisition II's fiscal year end?
Drugs Made In America Acquisition II's fiscal year end, as registered with the SEC, is December 31.
Where is Drugs Made In America Acquisition II headquartered?
Drugs Made In America Acquisition II lists its business address in New York, New York in its SEC filings.